TrialCompletion date type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Primary completion date
Recorded edit− Previous value
2026-05
+ Updated value
2026-06-16
NCT05425940Phase 3Active not recruiting
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Study sponsor: Exelixis
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2026-06-16Actual
Enrollment · participants901Actual
Source updated2026-07-17Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Overall Survival
+ Updated value
measure: Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized Participants; measure: Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in Randomized Non-Liver Metastases (NLM) Participants
The saved outcome text may be shortened. Check the source for full wording.
Participant count type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Enrollment · participant count
Recorded edit− Previous value
count: 874; type: ESTIMATED
+ Updated value
count: 901; type: ACTUAL
Primary completion date
Recorded edit− Previous value
2025-08
+ Updated value
2026-05